• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1279134 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
0 [1 A6 D2 }. j5 j+ Y* hNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
& Y, T- w2 m! ~- C! }. D; W- h' r+ Author Affiliations  H; x  o+ T( ~: F6 P& B: J) z$ n

! s5 Q- ~# Z. P" X( G1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( j  c' s- x5 [  q% _2 q2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ( S/ P4 J+ ?% N+ ]0 g8 u
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
, a* ^# v: m( [% g4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 D+ I/ Z7 O8 C6 B! ?  q+ P% ~) h5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan # u& D) B. O* y( j! S
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 g4 J) h( m6 u9 U1 K7Kinki University School of Medicine, Osaka 589-8511, Japan
" K- t: I, t" r& e/ h8Izumi Municipal Hospital, Osaka 594-0071, Japan 8 r% D; a, I" A% j
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& _( R7 Y+ X: yCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp + T* h7 H; @9 _9 Y4 Z( }! a
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. # z0 ^$ ?% w6 ^1 a: b! k. s

, A3 G" {' r+ H8 u8 V
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
7 C1 z% v  l# N+ B  N1 \1 ^
$ c( z. i1 G7 ]$ r( R& ]/ |0 lAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
) [) U5 G. I- Y; z5 T- A/ V$ {6 y* A6 Z0 M
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ! q0 Q4 U! ?+ {9 O- |

5 g% A. z: U: D' s% V" `- i2 oPublished online on: Thursday, December 1, 2011
  x. O4 M' {  X6 x3 n; Z
0 l/ d. ?" t! u3 vDoi: 10.3892/ol.2011.507 - l" t8 X3 n1 {: W; i

+ Y6 v# C3 V$ ~8 q" `Pages: 405-410 * j3 `8 K# ?  X' D+ J5 H
% P8 m8 o5 S/ L. Y5 h9 D
Abstract:2 Y/ d  ^. m( m( _5 \" ^
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma./ i) I8 i! p( c& B( Q

# \8 {! b5 ^$ J1 \1 m8 Q
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
3 ]- C# d9 {& W$ x- rF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 : d' Y8 ^' H! E7 s
+ Author Affiliations" N6 f! N/ R- U$ M8 a1 W5 i
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu " {2 o1 Q9 j/ L2 W# S+ O4 ^) r; c
2Department of Thoracic Surgery, Kyoto University, Kyoto 3 g2 {: ^/ u! K- F7 Y8 I
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
0 ?# R/ n- e6 J8 p&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 3 U  t) b$ V6 I; f
Received September 3, 2010.
+ P$ `( A7 ?, T! ]+ W! Z( PRevision received November 11, 2010. . R2 |" W- r; o1 V; J. o1 P
Accepted November 17, 2010. % M5 }  _4 q# V1 ]
Abstract
: }7 W6 r4 Y0 d* b. @/ sBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
* D5 \5 P% E& j* i' |- |Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
4 K4 c/ J: z+ |+ o$ |1 N, E5 gResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
. g# H7 G& k; E+ _* w7 B7 jConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. / ]- z% m: |) G# o6 v0 z4 V; @9 ?
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
) U! b& a, ^: g# e/ K$ K今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
7 c' T+ c. e+ d7 l8 u. p
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy& o, m8 _% s  E' r
http://clinicaltrials.gov/ct2/show/NCT01523587
0 O9 N0 ~* Z# R0 d; K+ i8 _
% _% D; A- A* h( B9 U* ^) IBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC6 Y' w) i" E2 K$ G# J6 W4 c) B3 F1 V
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 1 D2 I9 V, F% o8 h$ Z0 G6 d
! Z0 o9 W1 {; f7 B
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
7 `- p: Z9 f! P- M8 _3 a. K至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 0 @- {* {# e3 n4 j" D+ R6 l6 G2 C
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: d  @. u: j5 i7 E/ ^" q至今为止,未出 ...
, k0 \% d" U9 ?$ p, F% M
没有副作用是第一追求,效果显著是第二追求。
2 N' q; ?$ U0 W8 T9 G; w不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表